Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Andes virus DNA vaccine

Phase 1Vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Andes virus DNA vaccine is one of 2 biologic programs targeting Hantavirus Pulmonary Syndrome. It is currently in Phase 1.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hantavirus Pulmonary SyndromeActive, not recruiting

Hantavirus Pulmonary SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Hantavirus Pulmonary Syndrome

#DrugCompanyPhaseTrials

Virazole

CConrado Roberto Hoffmann Filho

Andes virus DNA vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hantavirus Pulmonary Syndrome1 trial

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT03682107·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Andes virus DNA vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Andes virus DNA vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Andes virus DNA vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Allergy and Infectious Diseases (NIAID) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Allergy and Infectious Diseases (NIAID)

Related News